BLFSBioLife Solutions, Inc.

$38.58+50% 1Y

$38.58

$18.1552 weeks$39.24

BLFS in its own filings

BLFS's filing record carries 4 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

426

Events found in the filings · across 1,733 filings · the record starts in 1995

Hard flags: 4
Hard flags
Most recent filing: Oct 6, 2026
Most recent filing · Form 25-NSE
Record starts: May 15, 1995
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 5, 2026
Restatement admitted (non-reliance)historical: 2020-04-30
Change in certifying accountant4 occurrences: 2022-04-07
Late periodic report19 occurrences: 2023-05-11
Delisting notice / listing-rule failurehistorical: 2022-03-18
Security removed from listing or deregisteredcurrent · usually a matured note or preferred class, not the common shares: 2026-10-06
SEC comment-letter activity35 occurrences: 2023-11-30

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 6, 2026At the effective time of the First Merger (the “First Merger Effective Time”), each share of BioLife’s common stock, par value $0.001 per share (“BioLife Common Stock”), issued and outstanding immediately prior to the First Merger Effective Time (other than (i) any shares that were held by BioLife in treasury or owned …Acquisition or disposition completed · Form 8-K
Sep 9, 2026As previously disclosed, on July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Repligen Corporation, a Delaware corporation (“Repligen”), Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of …Other event · Form 8-K
Jul 22, 2026Merger Agreement On July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among, BioLife, Repligen Corporation, a Delaware corporation (“Repligen”), Bravo Merger Sub I, Inc., a Delaware corporation and …Material agreement entered · Form 8-K
Jan 9, 2026On January 8, 2026, Karen Foster, the Chief Quality and Operations Officer of BioLife Solutions, Inc. (the “Company”), provided notice of her decision to retire from her position as Chief Quality and Operations Officer of the Company, effective March 31, 2026.Director or officer change · Form 8-K